Drug Type Universal CAR-T |
Synonyms LEU-006 |
Target |
Action antagonists |
Mechanism NKG2D antagonists(NKG2-D type II integral membrane protein antagonists), Gene transference(Gene transference), T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Preclinical | United Kingdom | 24 Apr 2022 |